Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines

Biotechnology Progress

Volumn 14, Issue 1, 1998, Pages 102-107

  Cleland, Jeffrey L ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC POLYMERS; BIODEGRADATION; CARBOXYLIC ACIDS; DRUG DOSAGE; EVAPORATION; PROTEINS; VACCINES;

POLYGLYCOLIC ACID; POLYLACTIC ACID; SOLVENT EVAPORATION;

CONTROLLED DRUG DELIVERY;

BIOMATERIAL; LACTIC ACID; MICROSPHERE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; PROTEIN; SOLVENT; VACCINE;

ARTICLE; BIOREMEDIATION; DELAYED RELEASE FORMULATION;

BIOCOMPATIBLE MATERIALS; BIODEGRADATION, ENVIRONMENTAL; DELAYED-ACTION PREPARATIONS; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; PROTEINS; SOLVENTS; VACCINES;

EID: 0031933272     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp970128t     Document Type: Article

References (22)

1. Cleland, J. L.; Langer, R. Formulation and delivery of proteins and peptides: Design and development strategies. In Protein Formulations and Drug Delivery; Cleland, J. L., Langer, R. Eds.; AGS Symposium Series, Vol. 567; American Chemical Society: Washington, DC, 1994; pp 1-21.
2. Cleland, J. L. Protein delivery from biodegradable microspheres. In Protein Delivery: Physical Systems; Sanders, L., Hendren, W., Eds.; Plenum: New York, 1997; pp 1-43.
3. Okada, H.; Inoue, Y.; Heya, T.; Ueno, H.; Ogawa, Y.; Toguchi, H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 1991, 8, 787-791.
4. Sharifi, R.; Bruskewitz, R. C.; Gittleman, M. C.; Graham, S. D., Jr.; Hudson, P. B.; Stein, B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin. Ther. 1996, 18, 647-657.
5. Austin, P. E.; Dunn, K. A.; Elly-Cofield, K.; Brown, C. K.; Wooden, W. A.; Bradfield, J. F. Subcuticular sutures and the rate of inflammation in noncontaminated wounds. Ann. Emerg. Med. 1995, 25, 328-330.
6. Kissel, T.; Koneberg, R. Injectable biodegradable microspheres for vaccine delivery. In Microparticulate systems for the delivery of proteins and vaccines; Cohen, S., Bernstein, H. Eds.; Dekker: New York, 1996; pp 51-88.
7. Morris, W.; Steinhoff, M. C.; Russell, P. K. Potential of polymer microencapsulation technology for vaccine innova- tion. Vaccine 1994, 12, 5-11.
8. Theis, C. Formation of degradable drug-loaded micropar- ticles by in-liquid drying processes. In Microcapsules and nanoparticles in medicine and pharmacy; Donbrow, M., Ed.; CRC Press: London, 1992; pp 47-71.
9. Schwendeman, S. P.; Costantino, H. R.; Gupta, R. K.; Klibanov, A. M.; Langer, R. L. Peptide, protein, and vaccine delivery from implantable polymer systems. In Controlled drug delivery: challenges and strategies; Park, K., Ed.; American Chemical Society: Washington, DC, 1997; pp 229-267.
10. Cleland, J. L. Design and production of single immunization vaccines using polylactide polyglycolide microsphere systems. In Vaccine Design: The Subunit Approach; Powell, M. F., Newman, M., Eds.; Plenum Publishing: New York, 1995; pp 439-472.
11. Cleland, J. L.; Lim, A.; Barrón, L.; Duenas, E. T.; Powell, M. F. Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation and pulsatile release of MN rgp120 from biodegradable microspheres. J. Controlled Release 1997, 47, 135-150.
12. Cleland, J. L.; Duenas, E. T.; Daugherty, A. L.; Marian, M.; Yang, J.; Wilson, M. Celniker, A. C.; Shahzamani, A.; Quarmby, V.; Chu, H.; Mukku, V.; Mac, A.; Roussakis, M.; Gillette, N.; Boyd, B.; Yeung, D.; Brooks, D.; Maa, Y.-F.; Hsu, C.; Jones, A. J. S. Recombinant human growth hormone poly- (lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J. Controlled Release 1997, in press.
13. Tauber, H.; De Bouet Du Portal, H.; Sallerin-Caute, B.; Rochiccioli, P.; Bastide, R. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J. Clin. Endocrinol. Metab. 1993, 76, 1135-1139.
14. Cleland, J. L.; Jones, A. J. S. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable polymers. Pharm. Res. 1996, 13, 1462-1473.
15. Cleland, J. L.; Mac, A.; Boyd, B.; Yang, J.; Duenas, E. T.; Yeung, D.; Brooks; D.; Hsu, C.; Chu, H.; Mukku, V.; Jones, A. J. S. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) PLGA microspheres. Pharm. Res. 1997, 14, 420-425.
16. Cleland, J. L.; Johnson, O. L.; Putney, S. D.; Jones, A. J. S. Recombinant human growth hormone poly(lactic-coglycolic acid) microsphere formulation development. Adv. Drug Delivery Rev. 1997, in press.
17. Yang, J.; Cleland, J. L. Effect of analysis methods on the in vitro release of recombinant human interferon-γ (rhIFN-γ) from PLGA microspheres. J. Pharm. Sci. 1997, 86, 908-914.
18. Cleland, J. L.; Barrón, L.; Berman, P. W.; Daugherty, A.; Gregory, T.; Lim; A.; Vennari, J.; Wrin, T.; Powell, M. F. Development of a single-shot subunit vaccine for HIV-1: Part 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J. Pharm. Sci. 1996a, 85, 1346-1349.
19. Cleland, J. L.; Barrón, L.; Daugherty, A.; Eastman, D.; Kensil, C.; Lim, A.; Weissburg, R. P.; Wrin, T.; Vennari, J.; Powell, M. F. Development of a single-shot subunit vaccine for HIV-1: Part 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. 1996, 85, 1350-1357.
20. Cleland, J. L.; Powell, M. F.; Lim, A.; Barrón, L.; Berman, P.; Eastman, D.; Nunberg, J.; Wrin, T.; Vennari, J. Development of a single shot subunit vaccine for HIV-1. AIDS Res. Hum. Retroviruses 1994, 10, S21-S25.
21. Kaslow, D. C.; Shiloach, J. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose, Bio/Technology 1994, 12, 494-499.
22. Cleland, J. L.; Duenas, E. T.; Kaslow, D. C. Single administration malaria transmission-blocking PLGA vaccine. Proc. Int. Symp. Controlled Release Bioact. Mater. 1997, 24, 893-894.